Israel Lowy

Also affiliated with Progenics Pharmaceuticals (United States)

MedicineImmunology and Microbiology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

2in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 2 indexed papers attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Papers

Driven by 7 papers. Top paper: “Anti-PD-1 immunotherapy with androgen deprivation therapy induces robust immune infiltration in metastatic castration-sensitive prostate cancer”.

Anti-PD-1 immunotherapy with androgen deprivation therapy induces robust immune infiltration in metastatic castration-sensitive prostate cancer

Cancer Cell(2023)10.1016/j.ccell.2023.10.006

N/A

1.6DataRank · unranked

80 citations

Aleksandar Obradović, Matthew C. Dallos, Emerson A. Lim, Karie Runcie, Casey R. Ager +16 more

Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates

Journal of Clinical Oncology(2010)10.1200/jco.2009.26.7609

N/A

1.2DataRank · unranked

2920 citations

Charles G. Drake, Ira Wollner, John D. Powderly, Joel Picus, William H. Sharfman +15 more

T cell profiling reveals high CD4+CTLA-4+ T cell frequency as dominant predictor for survival after Prostate GVAX/ipilimumab treatment

Cancer Immunology, Immunotherapy(2013)10.1007/s00262-012-1330-5

N/A

0.678DataRank · unranked

91 citations

Anita G. M. Stam, Sinéad M. Lougheed, Helen Gall, Petra E. T. Scholten, Martine Reijm +11 more

PD-1 blockade in recurrent or metastatic cervical cancer: Data from cemiplimab phase I expansion cohorts and characterization of PD-L1 expression in cervical cancer

Gynecologic Oncology(2020)10.1016/j.ygyno.2020.08.026

N/A

0.650DataRank · unranked

75 citations

Marta Gil-Martin, Antonio González-Martin, Irene Braña, June Y. Hou, Daniel Cho +17 more

The PRIME-CUT study: A single-arm phase 2 study of ADT with PD-1 blockade and docetaxel in men with metastatic hormone-sensitive prostate cancer.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.e17089

N/A

0.165DataRank · unranked

2 citations

Matthew C. Dallos, Emerson A. Lim, Karie Runcie, Jianhua Hu, Israel Lowy +3 more

CLINICAL RESPONSES TO ODRONEXTAMAB (REGN1979): CORRELATION WITH LOSS OF CD20 EXPRESSION AS A POTENTIAL MECHANISM OF RESISTANCE AND BASELINE BIOMARKERS OF TUMOR T CELLS

Hematological Oncology(2021)10.1002/hon.6_2880

N/A

0DataRank · unranked

1 citations

Nathalie Fiaschi, Raquel P. Deering, Ankur Dhanik, Kamil J. Cygan, W Zhang +19 more

Single-Cell RNAseq Analysis Reveals Robust, Anti-PD-1-Mediated Increase of Immune Infiltrate in Metastatic Castration-Sensitive Prostate Cancer

bioRxiv (Cold Spring Harbor Laboratory)(2022)10.1101/2022.05.06.490968

N/A

0DataRank · unranked

2 citations

Aleksandar Obradović, Matthew C. Dallos, Emerson A. Lim, Karie Runcie, Casey R. Ager +15 more